Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenon
Mycobacterium indicus pranii (MIP) vaccine is widely used in dermatology as immunotherapy for warts as well as in patients with leprosy. During the COVID-19 pandemic, a positive role of MIP as an immunomodulator in SARS-CoV-2 disease was reported after pilot research, with minor adverse effects. We...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Journal of the Egyptian Women’s Dermatologic Society |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jewd.jewd_41_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560290418753536 |
|---|---|
| author | Pooja Agarwal Raju Chaudhary Kalgi Baxi Malhar Shah |
| author_facet | Pooja Agarwal Raju Chaudhary Kalgi Baxi Malhar Shah |
| author_sort | Pooja Agarwal |
| collection | DOAJ |
| description | Mycobacterium indicus pranii (MIP) vaccine is widely used in dermatology as immunotherapy for warts as well as in patients with leprosy. During the COVID-19 pandemic, a positive role of MIP as an immunomodulator in SARS-CoV-2 disease was reported after pilot research, with minor adverse effects. We report a case of a 65-year-old male, presenting with skin lesions suggestive of noninfective granulomatous dermatitis for 4 months, at the sites of MIP intradermal injections, allegedly received during a hospital stay for severe COVID-19 disease. The patient presented with nonhealing nodulo-ulcerative lesions at the sites of injection, which persisted for 4 months associated with intermittent serous discharge and showed no signs of healing despite supportive treatment. The patient was started on a combination therapy of ofloxacin 400 mg /day and clarithromycin 500 mg 12 hourly for 2 months. At the end of 2 months, all the lesions showed complete healing with a resolution of discharge and nodularity, leaving behind postinflammatory hypopigmentation and atrophic scarring. The patient was followed up for 4 months after stopping treatment during which time he had no relapse of the lesions. This case has been reported to the India Pharmacopoeia. |
| format | Article |
| id | doaj-art-aa7757eaa3234d30b8bca6c7f5b514d2 |
| institution | Kabale University |
| issn | 2090-2565 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of the Egyptian Women’s Dermatologic Society |
| spelling | doaj-art-aa7757eaa3234d30b8bca6c7f5b514d22025-01-04T14:15:16ZengWolters Kluwer Medknow PublicationsJournal of the Egyptian Women’s Dermatologic Society2090-25652024-01-01211758010.4103/jewd.jewd_41_23Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenonPooja AgarwalRaju ChaudharyKalgi BaxiMalhar ShahMycobacterium indicus pranii (MIP) vaccine is widely used in dermatology as immunotherapy for warts as well as in patients with leprosy. During the COVID-19 pandemic, a positive role of MIP as an immunomodulator in SARS-CoV-2 disease was reported after pilot research, with minor adverse effects. We report a case of a 65-year-old male, presenting with skin lesions suggestive of noninfective granulomatous dermatitis for 4 months, at the sites of MIP intradermal injections, allegedly received during a hospital stay for severe COVID-19 disease. The patient presented with nonhealing nodulo-ulcerative lesions at the sites of injection, which persisted for 4 months associated with intermittent serous discharge and showed no signs of healing despite supportive treatment. The patient was started on a combination therapy of ofloxacin 400 mg /day and clarithromycin 500 mg 12 hourly for 2 months. At the end of 2 months, all the lesions showed complete healing with a resolution of discharge and nodularity, leaving behind postinflammatory hypopigmentation and atrophic scarring. The patient was followed up for 4 months after stopping treatment during which time he had no relapse of the lesions. This case has been reported to the India Pharmacopoeia.https://journals.lww.com/10.4103/jewd.jewd_41_23covid-19 infectioncutaneous ulcersgranulomatous dermatitismycobacterium indicus pranii (mip) vaccineulcerated verrucous nodules |
| spellingShingle | Pooja Agarwal Raju Chaudhary Kalgi Baxi Malhar Shah Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenon Journal of the Egyptian Women’s Dermatologic Society covid-19 infection cutaneous ulcers granulomatous dermatitis mycobacterium indicus pranii (mip) vaccine ulcerated verrucous nodules |
| title | Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenon |
| title_full | Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenon |
| title_fullStr | Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenon |
| title_full_unstemmed | Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenon |
| title_short | Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenon |
| title_sort | granulomatous dermatitis post mycobacterium indicus pranii mip vaccine in severe covid 19 infection an exaggerated hypersensitivity phenomenon |
| topic | covid-19 infection cutaneous ulcers granulomatous dermatitis mycobacterium indicus pranii (mip) vaccine ulcerated verrucous nodules |
| url | https://journals.lww.com/10.4103/jewd.jewd_41_23 |
| work_keys_str_mv | AT poojaagarwal granulomatousdermatitispostmycobacteriumindicuspraniimipvaccineinseverecovid19infectionanexaggeratedhypersensitivityphenomenon AT rajuchaudhary granulomatousdermatitispostmycobacteriumindicuspraniimipvaccineinseverecovid19infectionanexaggeratedhypersensitivityphenomenon AT kalgibaxi granulomatousdermatitispostmycobacteriumindicuspraniimipvaccineinseverecovid19infectionanexaggeratedhypersensitivityphenomenon AT malharshah granulomatousdermatitispostmycobacteriumindicuspraniimipvaccineinseverecovid19infectionanexaggeratedhypersensitivityphenomenon |